PSMA PET/CT引导放疗在前列腺癌根治术后生化持续或复发患者中的结局
中位随访20个月,未接受抗雄治疗的患者中89%达到PSA≤0.2 ng/ml。PSMA PET/CT引导放疗是有效的局部挽救治疗,可显著降低PSA并推迟长期ADT或全身治疗。
要点
- PSMA PET/CT引导放疗对术后生化持续或复发患者有效,89%未用ADT者PSA≤0.2 ng/ml。
- 生化持续患者更多为高危且PSMA PET/CT更常显示淋巴结受累。
- 放疗后PSA≤0.1 ng/ml及生化复发类型与末次随访PSA≤0.2 ng/ml显著相关。
核心结论
- PSMA PET/CT引导放疗是前列腺癌根治术后生化复发或持续的有效局部挽救治疗,可显著降低PSA并推迟长期ADT或全身治疗。
主要发现
- 生化持续患者较高危比例显著更高,且PSMA PET/CT前时间间隔显著更短。
- 生化复发患者PSMA PET/CT更常无病灶或仅局部复发,生化持续患者更常淋巴结受累。
- 放疗后中位PSA为0.07 ng/ml,74%患者PSA≤0.1 ng/ml。
- 中位随访20个月,末次随访未用抗雄治疗的PET阳性患者(45例)中位PSA为0.05 ng/ml,89%总体、94%生化复发和82%生化持续患者PSA≤0.2 ng/ml。
关键数值与推荐
- 累计剂量:局部宏观肿瘤70(66-70.6)Gy,前列腺床66(63-66)Gy,PET阳性淋巴结61.6(53.2-66)Gy,淋巴引流区50.4(45-52.3)Gy。
- 生化无复发生存定义为PSA≤0.2 ng/ml。
- 放疗后PSA≤0.1 ng/ml及生化复发 vs. 持续与末次随访PSA≤0.2 ng/ml显著相关。
临床怎么用
- 对根治性前列腺切除术后生化持续或复发且无远处转移的患者,可考虑PSMA PET/CT引导的挽救性放疗。
- 根据PSMA PET/CT结果对局部宏观肿瘤、前列腺床、PET阳性淋巴结及淋巴引流区给予相应剂量照射。
- 该策略可显著降低PSA,有助于推迟长期ADT或全身治疗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: PSMA PET/CT visualises prostate cancer residual disease or recurrence at lower PSA levels compared to conventional imaging and results in a change of treatment in a remarkable high number of patients. Radiotherapy with dose escalation to the former prostate bed has been associated with improved biochemical recurrence-free survival. Thus, it can be hypothesised that PSMA PET/CT-based radiotherapy might improve the prognosis of these patients. METHODS: One hundred twenty-nine patients underwent PSMA PET/CT due to biochemical persistence (52%) or recurrence (48%) after radical prostatectomy without evidence of distant metastases (February 2014-May 2017) and received PSMA PET/CT-based radiotherapy. Biochemical recurrence free survival (PSA ≤ 0.2 ng/ml) was defined as the study endpoint. RESULTS: Patients with biochemical persistence were significantly more often high-risk patients with significantly shorter time interval before PSMA PET/CT than patients with biochemical recurrence. Patients with biochemical recurrence had significantly more often no evidence of disease or local recurrence only in PSMA PET/CT, whereas patients with biochemical persistence had significantly more often lymph node involvement. Seventy-three patients were started on antiandrogen therapy prior to radiotherapy due to macroscopic disease in PSMA PET/CT. Cumulatively, 70 (66-70.6) Gy was delivered to local macroscopic tumor, 66 (63-66) Gy to the prostate fossa, 61.6 (53.2-66) Gy to PET-positive lymph nodes and 50.4 (45-52.3) Gy to lymphatic pathways. Median PSA after radiotherapy was 0.07 ng/ml with 74% of patients having a PSA ≤ 0.1 ng/ml. After a median follow-up of 20 months, median PSA was 0.07 ng/ml with ongoing antiandrogen therapy in 30 patients. PET-positive patients without antiandrogen therapy at last follow-up (45 patients) had a median PSA of 0.05 ng/ml with 89% of all patients, 94% of patients with biochemical recurrence and 82% of patients with biochemical persistence having a PSA ≤ 0.2 ng/ml. Post-radiotherapy PSA ≤ 0.1 ng/ml and biochemical recurrence vs. persistence were significantly associated with a PSA ≤ 0.2 ng/ml at last follow-up. CONCLUSIONS: PSMA PET/CT-based radiotherapy is an effective local salvage treatment option with significant PSA response in patients with biochemical recurrence or persistence after radical prostatectomy leading to deferral of long-term ADT or systemic therapy.
引用
- Schmidt-Hegemann NS, Fendler WP, Ilhan H, et al. Outcome after PSMA PET/CT based radiotherapy in patients with biochemical persistence or recurrence after radical prostatectomy. Radiat Oncol. 2018. PMID: 29499730. doi:10.1186/s13014-018-0983-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。